Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H1D9

UPID:
RPC6_HUMAN

ALTERNATIVE NAMES:
DNA-directed RNA polymerase III subunit F; RNA polymerase III 39 kDa subunit

ALTERNATIVE UPACC:
Q9H1D9; A8K4C7; O15319

BACKGROUND:
The DNA-directed RNA polymerase III subunit F, alternatively known as RNA polymerase III 39 kDa subunit, is integral to synthesizing small RNAs and plays a key role in the body's defense against intracellular pathogens. Its ability to sense non-self dsDNA and initiate an innate immune response through the RIG-I pathway is critical for limiting viral infections, including those caused by varicella zoster virus.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Immunodeficiency 101, varicella zoster virus-specific, the study of DNA-directed RNA polymerase III subunit F offers promising avenues for therapeutic intervention. Exploring its function and mechanisms could lead to novel treatments for this and related immunodeficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.